Research Coverage of Japanese Listed Companies, Shared Research Inc

Shared Research

Research Coverage of Japanese Listed Companies

Shared Research Inc

Pioneering research coverage of Japanese listed companies. Now customizable and interactive for global institutional investors. Corporate access reimagined.

Equity Bottom-Up

<ul><li>The company reported sales of JPY94.2bn (+8.9% YoY), operating profit of JPY1.6bn, and recurring profit of JPY1.5bn.</li><li>Dispensing Pharmacy business sales reached JPY84.0bn (+9.6% YoY) with operating profit rising to JPY3.0bn (+72.6% YoY).</li><li>Pharmaceutical Manufacturing and Sales business sales rose to JPY10.5bn (+5.7% YoY) with operating profit at JPY123mn.</li></ul>

The company reported sales of JPY94.2bn (+8.9% YoY), operating profit of JPY1.6bn, and recurring profit of JPY1.5bn.Dispensing Pharmacy business sales reached JPY84.0bn (+9.6% YoY) with operating profit rising to JPY3.0bn (+72.6% YoY).Pharmaceutical Manufacturing and Sales business sales rose to JPY10.5bn (+5.7% YoY) with operating profit at JPY123mn.

Nihon Chouzai (3341 JP): Q1 FY03/26 flash update

<ul><li>Sales increased by 5.9% YoY to JPY360.5bn, but operating profit decreased by 31.8% YoY to JPY6.2bn. </li><li>Pharmaceutical Manufacturing faced a JPY630mn operating loss due to NHI drug price revisions and manufacturing deficiencies. </li><li>FY03/26 forecasts sales of JPY372.8bn (+3.4% YoY) and net income of JPY3.5bn (+151.6% YoY).</li></ul>

Sales increased by 5.9% YoY to JPY360.5bn, but operating profit decreased by 31.8% YoY to JPY6.2bn. Pharmaceutical Manufacturing faced a JPY630mn operating loss due to NHI drug price revisions and manufacturing deficiencies. FY03/26 forecasts sales of JPY372.8bn (+3.4% YoY) and net income of JPY3.5bn (+151.6% YoY).

Nihon Chouzai (3341 JP): Full-year FY03/25 flash update

<ul><li>Sales increased by 5.6% YoY to JPY175.6bn, but operating profit decreased by 87.5% YoY to JPY423mn.</li><li>Pharmaceutical Manufacturing and Sales business faced a 4.5% YoY sales decline to JPY19.6bn, with an operating loss of JPY652mn.</li><li>Sales in the pharmacist staffing and physician placement business rose 21.8% YoY to JPY6.0bn, with operating profit up 9.7% YoY.</li></ul>

Sales increased by 5.6% YoY to JPY175.6bn, but operating profit decreased by 87.5% YoY to JPY423mn.Pharmaceutical Manufacturing and Sales business faced a 4.5% YoY sales decline to JPY19.6bn, with an operating loss of JPY652mn.Sales in the pharmacist staffing and physician placement business rose 21.8% YoY to JPY6.0bn, with operating profit up 9.7% YoY.

Nihon Chouzai (3341 JP): 1H FY03/25 flash update

<ul><li>Sales reached JPY86.4bn (+5.6% YoY), operating loss was JPY236mn, recurring profit was JPY85mn, net loss was JPY140mn.</li><li>Sales were JPY76.6bn (+6.0% YoY), operating profit was JPY1.7bn (-40.5% YoY), 7 new pharmacies opened, 2 closed.</li><li>Sales were JPY9.9bn (-5.6% YoY), operating loss was JPY461mn, 492 products offered, 47.6% in-house manufactured products.</li></ul>

Sales reached JPY86.4bn (+5.6% YoY), operating loss was JPY236mn, recurring profit was JPY85mn, net loss was JPY140mn.Sales were JPY76.6bn (+6.0% YoY), operating profit was JPY1.7bn (-40.5% YoY), 7 new pharmacies opened, 2 closed.Sales were JPY9.9bn (-5.6% YoY), operating loss was JPY461mn, 492 products offered, 47.6% in-house manufactured products.

Nihon Chouzai (3341 JP): Q1 FY03/25 flash update

<ul>
<li>
<a href="https://www.smartkarma.com/entities/nihon-chouzai-co-ltd" target="_blank" data-smartkarma-citation="entities:5873:1" rel="noopener">Nihon Chouzai (3341 JP)</a> is an integrated healthcare company whose core business is the operation of dispensing pharmacies.</li>
<li>In FY03/23, Nihon Chouzai reported sales of JPY313.3bn, operating profit of JPY7.6bn, recurring profit of JPY7.7bn, and net income attributable to owners of the parent of JPY4.5bn.</li>
<li>Nihon Chouzai Co., Ltd. announced the retirement of treasury shares.</li>
</ul>



Nihon Chouzai (3341 JP) is an integrated healthcare company whose core business is the operation of dispensing pharmacies.
In FY03/23, Nihon Chouzai reported sales of JPY313.3bn, operating profit of JPY7.6bn, recurring profit of JPY7.7bn, and net income attributable to owners of the parent of JPY4.5bn.
Nihon Chouzai Co., Ltd. announced the retirement of treasury shares.


Japan

NIHON CHOUZAI Co., Ltd. operates a drug store chain in Japan.  The Company manages drug prescriptions, orders, and inventories of all stores through an online system.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Nihon Chouzai (3341 JP)